Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
This retrospective study aims to assess the clinical and economic impact of early initiation
 of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP)
 receiving 5ARI monotherapy or combination therapy with an alpha-blocker (AB) compared to late
 initiation of 5ARI therapy in patients receiving combination therapy. The Henry Ford Health
 System databases will be utilized for this study (2000-2008).
Inclusion Criteria:

 -  Males

 -  aged 50 years or older

 -  medical claim of EP

 -  prescription claim(s) for either a 5ARI or both 5ARI and AB (provided both are within
 180 days of index date)

 -  continuously eligible for 3 months prior to and at least 5 months after their index
 prescription date.

 Exclusion Criteria:

 -  Patients with prostate or bladder cancer

 -  any prostate-related surgical procedure within 5 months of index date

 -  prescription claim for finasteride indicative of male pattern baldness; AB monotherapy
 only; initiation of 5ARI occurring more than 180 days after initiation of AB